Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-658-1 | CAS number: 123-86-4
Carcinogenicity
Administrative data
Description of key information
In accordance with column 2 of REACH Annex X No. 8.9.1, the study does not need to be conducted as
- in all in vitro and in vivo genotoxitity studies performed, no evidence was found that the substance induced any mutagenic or genotoxic response and
- there was no evidence from the repeated dose studies that the substance is able to induce hyperplasia or pre-neoplastic lesions.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
There is no evidence for a muutagenic or carcinogenic potential of n-Butyl Acetate. Therefore a carcinogenicity classification is not justified.
Additional information
In accordance with column 2 of REACH Annex X No. 8.9.1, the study does not need to be conducted as
- in all in vitro and in vivo genotoxitity studies performed, no evidence was found that the substance induced any mutagenic or genotoxic response and
- there was no evidence from the repeated dose studies that the substance is able to induce hyperplasia or pre-neoplastic lesions.
Justification for selection of carcinogenicity via oral route endpoint:
No carcinogenicity study is required, since the substance is not mutagenic and no hyperplasia or pre-neoplastic lesions were observed in any available studies.
Justification for selection of carcinogenicity via inhalation route endpoint:
No carcinogenicity study is required, since the substance is not mutagenic and no hyperplasia or pre-neoplastic lesions were observed in any available studies.
Justification for selection of carcinogenicity via dermal route endpoint:
No carcinogenicity study is required, since the substance is not mutagenic and no hyperplasia or pre-neoplastic lesions were observed in any available studies.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
